National Jewish Health

About: National Jewish Health is a healthcare organization based out in Denver, Colorado, United States. It is known for research contribution in the topics: T cell & Asthma. The organization has 883 authors who have published 833 publications receiving 79201 citations. The organization is also known as: National Jewish Medical and Research Center.

Surfactant lipids, compositions thereof, and uses thereof

Abstract: The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.

Methods for Categorizing and Treating Subjects at Risk for Pulmonary Exacerbation and Disease Progression

Abstract: The present invention is related to novel methods for categorizing and treating a population of subjects that are at risk for increased pulmonary exacerbation and disease progression.

Differential asthma risk following respiratory infection in children from three minority populations

Abstract: Rationale Severe early-life respiratory illnesses, particularly those caused by respiratory syncytial virus (RSV) and human rhinovirus (HRV), are strongly associated with the development of asthma in children. Puerto Rican children in particular have a strikingly high asthma burden, but prior studies of the potential associations between early-life respiratory illnesses and asthma in Puerto Rican and other minority populations have been limited. Objectives We sought to determine whether early-life respiratory illness was associated with asthma in Puerto Rican children relative to other minority children. Methods Using a logistic regression analysis, we examined the association between early-life respiratory illnesses (report of upper respiratory infection (URI), pneumonia, bronchitis, and bronchiolitis/RSV) within the first two years of life and physician-diagnosed asthma after the age of two in a large cohort of minority children. Measurements and Main Results Early-life respiratory illnesses were associated with greater asthma risk in Puerto Ricans relative to other racial/ethnic minority populations. Specifically, in Puerto Ricans, the odds was 6.15 (95% CI: 4.21-9.05) if the child reported at least one of the following respiratory illness: URI, pneumonia, bronchitis or bronchiolitis. The odds were also higher in Puerto Ricans when considering these conditions separately. Conclusions We observe population-specific associations between early-life respiratory illnesses and asthma, which was especially significant in Puerto Ricans. Taken together with the known high burden of RSV in Puerto Rico, our results may help explain the high burden of asthma in Puerto Ricans.

Methods and compositions for 10beryllium complex probes

Abstract: The present invention concerns methods and compositions for making and using Be complexes of defined compositions, which may have multiple functionalities and/or binding specificities. In various embodiment, Beryllium (Be) complexes may include Be such as 10Be and 7Be complexes. Such complexes find use in a wide variety of applications, particularly in the field of treatment, detection and/or diagnosis of infections, diseases and other health-related conditions, including but not limited to cancer, autoimmune disease, cardiovascular disease, metabolic diseases, degenerative diseases, and organ transplant rejection. In addition, a Be complex may be used in a BeLPT assay.

39. Cytokines, antiphospholipids, and cognition in nonNPSLE

Abstract: Introduction: Elevated N-methyl-D-aspartate (NMDA) receptor antibodies (anti-NR2) have been reported in 35% of patients with systemic lupus erythematosus (SLE) and may be associated with cognitive and memory dysfunction. Hypotheses: Anti-NR2 will be elevated in SLE patients with no prior overt neurological or psychiatric symptoms (nonNPSLE) compared to healthy controls. Elevated anti-NR2 will be associated with cognitive and memory dysfunction. Methods: Subjects included 29 nonNPSLE patients and 19 healthy control subjects with similar demographic characteristics. Cognitive function was assessed by administration of the ACR-SLE neuropsychological battery. A global cognitive impairment index (CII) and a memory impairment index (MII) were calculated using impaired test scores from the battery. Serum samples were obtained from all the participants; analyses were performed using a standard ELISA for anti-NR2. Results: Elevations of anti-NR2 were found in 13.8% of the nonNPSLE and 5.3% of the controls (p = 0.64). There was no relationship between elevated anti-NR2 status and higher CII or performance on the MII. Conclusions: The overall frequency of elevated anti-NR2 was low (13.8%) in our sample of SLE patients and not significantly dierent from controls. Mild SLE disease activity and exclusion of patients with neuropsychiatric features may have contributed to these findings. The lack of relationship between elevated anti-NR2 and cognitive or memory function suggests that NMDA may not be a significant contributor to the mechanism of cognitive or memory decline in nonNPSLE patients. Small sample size limits findings to date.